SonoVascular is a clinical-stage medical device firm focused on transforming venous thromboembolism (VTE) treatment with its SonoThrombectomy System, an ultrasound-facilitated, thrombolytic-enhanced thrombectomy platform that harnesses microbubble-mediated cavitation to dissolve clots without blood loss or vascular trauma. The cath-lab solution delivers ultrasound energy and microbubbles through the RESONATOR catheter, paired with low-dose tPA, to address deep vein thrombosis (DVT) and pulmonary embolism (PE) more safely and cost-effectively than existing therapies. In a South American first-in-human study, the device treated ten DVT patients, achieving 100% Marder score clot reduction and no device-related adverse events, with sustained clinical improvements at 30-day and six-month follow-ups. The company will use new capital to obtain FDA approval for a U.S. peripheral venous pivotal study and to initiate a first-in-human PE study in 2026. Management positions the technology as a single-session, cath-lab procedure that can ease ICU burdens and reduce healthcare costs. Financially, SonoVascular has completed a $6 million Series A first close, its first disclosed institutional round; no revenue or additional operating metrics were provided. The SonoThrombectomy System remains investigational and has not yet received FDA clearance.

Total raised

$6M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2026